Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

70.54 USD -0.92 (-1.29%)
Official Closing Price Updated: 7:59 PM EDT, Apr 9, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Sarepta Therapeutics Announces Fourth Year of Route 79, The Duchenne Scholarship Program
From GlobeNewswire News Releases
Sarepta Therapeutics’ Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and Functional Improvements 2 Years After Administrat
From GlobeNewswire News Releases
Sarepta Therapeutics to Present Results from its Gene Therapy and RNA Platforms at the 2021 Annual MDA Clinical and Scientific Conference
From GlobeNewswire News Releases
AavantiBio Bolsters Leadership Team with Appointment of Ty Howton as Chief Operating Officer and General Counsel
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, today announced the appointment of Ty Howton as Chief Operating Officer and General Counsel.... 
From Business Wire News Releases
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investor Notice: Investigation over Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 03/08/2021 -- Certain directors of Sarepta Therapeutics, Inc are under investigation concerning potential breaches of fiduciary duties. 
From SBWire - Latest Press Releases
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
From GlobeNewswire News Releases
Sarepta Therapeutics to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2020 Financial Results and Recent Corporate Developments on March 1, 2021
From GlobeNewswire News Releases
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPT
Pomerantz LLP is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or the "Company")(NASDAQ: SRPT). Such investors are advised to contact Robert S. Willoughby at... 
From PR Newswire
Sarepta Therapeutics Announces Winners of the “Rare Lessons” Lesson Planning Competition
From GlobeNewswire News Releases
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ:... 
From PR Newswire
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
NASDAQ:SRPT Shareholder Notice: Investigation over Potential Securities Laws Violations by Sarepta Therapeutics, Inc.
San Diego, CA -- (SBWIRE) -- 01/18/2021 -- Sarepta Therapeutics, Inc is under investigation over potential securities laws in connection with certain financial statements. 
From SBWire - Latest Press Releases
Sarepta Therapeutics and Genevant Sciences Announce Research Collaboration for Lipid Nanoparticle-Based Gene Editing Therapeutics
From GlobeNewswire News Releases
Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm
From GlobeNewswire News Releases
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. 
From Business Wire News Releases
SHAREHOLDER ALERT: Barr Law Group Investigating the Officers and Directors of SRPT, PS, RP, and PGZ; Shareholders are Encouraged to Contact the Firm
From GlobeNewswire News Releases
SRPT EQUITY ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc.; Encourages Investors with Losses Exceeding $1 Million to Contact Fir
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from... 
From PR Newswire
SRPT INVESTIGATION ALERT: Bernstein Liebhard is Investigating Sarepta Therapeutics, Inc. For Violations of the Securities Laws
Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Sarepta Therapeutics, Inc. ("Sarepta" or the... 
From PR Newswire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Sarepta Therapeutics, Inc. 
From Business Wire News Releases
SRPT EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Sarepta Therapeutics, Inc. – SRPT
Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) resulting from... 
From Business Wire News Releases
Sarepta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Sarepta Therapeutics Announces Executive Management Changes
From GlobeNewswire News Releases
Should you invest in General Electric, Sarepta Therapeutics, Carnival Corp, Boeing, or Caterpillar?
InvestorsObserver issues critical PriceWatch Alerts for GE, SRPT, CCL, BA, and CAT. 
From PR Newswire
Sarepta Therapeutics Announces Positive Clinical Results from MOMENTUM, a Phase 2 Clinical Trial of SRP-5051 in Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 51
From GlobeNewswire News Releases
Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular Dystrophy
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 8 9
...
31 32 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.